Study wrapper · #313
Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway.
Editor's note
A multi-part study pairing a small human observation with mechanistic animal and cell work on GHK-Cu and muscle wasting in COPD. In patients, researchers found lower plasma GHK in COPD (n=9) than in healthy controls (n=11), correlating with muscle area and inflammatory markers, an association from very small samples, hypothesis-generating at best. The core is preclinical: in cultured muscle cells and a cigarette-smoke mouse model, GHK-Cu was associated with preserved muscle mass, larger fibre size and improved grip strength, proposed to act by binding and activating SIRT1 and downstream pathways that curb protein breakdown and oxidative stress. These are animal and cell findings; human data are needed before clinical conclusions can be drawn. Note the route, intraperitoneal injection in mice, differs from human topical or community injection practice, and doses are not directly transferable. It is one of the more mechanistically detailed GHK-Cu muscle papers, but remains a preclinical signal in a smoke-exposure model, not evidence of benefit in people with COPD.
Plain-language abstract
Muscle weakness is a common and serious problem in people with COPD, a smoking-related lung disease. This study explored whether the natural copper peptide GHK might be involved. First, in people, researchers measured GHK in the blood and found lower levels in 9 COPD patients than in 11 healthy volunteers; lower GHK went along with smaller chest-muscle size and higher inflammation. Then they did the main experiments in muscle cells and in mice exposed to cigarette smoke. Giving GHK-Cu (GHK combined with copper) was linked to less muscle loss, larger muscle fibres, and stronger grip in the mice. The researchers traced this to GHK-Cu binding and switching on a protein called SIRT1, which in turn reduced muscle-protein breakdown, lowered oxidative stress, and supported the cells' energy factories (mitochondria). The human part was very small, and the main results come from cells and mice given the peptide by injection into the abdomen. Human trials would be needed before any conclusions for people with COPD.